Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain TMO message board posts where the ticker symbol TMO has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest TMO SEC Filings

Filings Format Description Filing Date File/Film Number
8-K  Documents Current report, item 5.02
Acc-no: 0000097745-18-000033 (34 Act)  Size: 29 KB
2018-09-07 001-08002
181060241
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001127602-18-026507 Size: 4 KB
2018-08-30
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001127602-18-026506 Size: 4 KB
2018-08-30
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001127602-18-026505 Size: 4 KB
2018-08-30
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001127602-18-026504 Size: 4 KB
2018-08-30
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001127602-18-026503 Size: 4 KB
2018-08-30
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001127602-18-026501 Size: 5 KB
2018-08-30
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001127602-18-026405 Size: 4 KB
2018-08-28
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001127602-18-026404 Size: 7 KB
2018-08-28
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001127602-18-026403 Size: 7 KB
2018-08-28
More TMO SEC Filings


Related news from
Fri, 21 Sep 2018
13:01:05 +0000
Is Abbott Laboratories Trading at a High Valuation in September?
On September 19, Abbott Laboratories (ABT) was trading at a forward PE multiple of 21.8x, while its trailing-12-month PE multiple was 52.4x. Its forward PE and trailing-12-month PE multiples were 19.2x and 55.7x, respectively, a few months ago in May.
Thu, 20 Sep 2018
16:17:04 +0000
Analysts Are Overwhelmingly Bullish on Abbott Laboratories
Abbott Laboratories (ABT) is one of the leading medical technology companies in the world. It offers products across its Medical Devices, Nutrition, Diagnostics, and Established Pharmaceuticals segments, with most of its products having the highest market shares in their respective markets. On July 18, the company released its most recent quarterly results and exceeded analysts’ estimates.
Thu, 20 Sep 2018
11:31:27 +0000
What Quest Diagnostics’ Valuation Trend Indicates
In September 2018, of the total 18 analysts covering Quest Diagnostics (DGX), ten analysts have given Quest stock a “buy” or higher rating, and eight analysts have given Quest a “hold” rating. The mean rating for Quest stock is 2.22 with a target price of $116.86 implying an upside potential of 9% over Quest’s closing price of $107.22 on September 18, 2018.
Wed, 19 Sep 2018
18:52:39 +0000
Taking Stock of Quest Diagnostics’ Recent Acquisitions
Quest Diagnostics’ (DGX) diagnostic information services (or DIS) business accounts for more than 95% of the company’s total revenues. It is characterized by a high volume of relatively low-dollar transactions. Under DIS, Quest provides clinical testing and other services. Major customer groups for DIS include healthcare insurers, government payers, client payers, and patients.
Wed, 19 Sep 2018
18:52:38 +0000
How Quest Diagnostics Is Positioned in 2018
Quest Diagnostics (DGX) is a leading provider of diagnostic information services. Quest makes use of its database of clinical lab results to gain diagnostic insights that help to improve healthcare management. Quest’s diagnostics information services business (or DIS) provides data and insights based on routine, non-routine, and advanced clinical testing, as well as anatomic pathology testing and other diagnostic information services.
Wed, 19 Sep 2018
17:12:24 +0000
What’s the Upside Potential of Thermo Fisher Scientific Stock?
So far in 2018, Thermo Fisher Scientific (TMO) stock has generated double-digit returns for investors. Boosted by its strong financial performance, it’s risen from $192.98 on January 2 to its current level of $240 in September.
Wed, 19 Sep 2018
17:12:23 +0000
What Thermo Fisher Scientific’s Gross Margin Trend Indicates
Thermo Fisher Scientific (TMO) is a leading provider of analytical instruments, equipment, reagents, and consumables. Thermo Fisher Scientific generated total revenue of $6.08 billion in the second quarter compared to $4.99 billion in the comparable period of 2017. Thermo Fisher generates revenue from product sales and services.
Wed, 19 Sep 2018
17:12:23 +0000
What’s Driving the Growth in Thermo Fisher Scientific’s Segments?
Thermo Fisher Scientific (TMO) operates in four business segments. The Analytical Instruments segment provides instruments, software, and services for use in laboratory applications. The segment’s revenue rose from $1.17 billion in the second quarter of 2017 to $1.31 billion in the second quarter of 2018 due to increased demand for chromatography and mass spectrometry and electron microscopy. This increase came from the strong performance of the healthcare market channel and clinical diagnostic products.
Tue, 18 Sep 2018
22:00:02 +0000
Cynosure Headwinds Trigger Analyst Downgrades on HOLX Stock
Hologic (HOLX) is a medical technology company focused on women’s health with headquarters in Marlborough, Massachusetts. The company offers solutions across four segments including diagnostics, breast and skeletal health, gynecological surgery, and medical aesthetics. The company recently provided an update on the financial impact of its recently announced marketing and distribution suspension of its TempSure Vitalia handpiece and probes. We discussed the details in the previous article of this series. ...
Tue, 18 Sep 2018
18:59:16 +0000
A Look at Hologic Stock’s Recent Performance
On September 17, Hologic (HOLX) ended the day at $39.53. The stock was down ~0.3% from its previous trading day’s closing price of $39.64. The stock has recuperated some of the losses it saw during the first half of fiscal 2018. It witnessed a declining trend after reporting its 52-week high of $45.09 on January 9, 2018.
Tue, 18 Sep 2018
12:59:12 +0000
Here's Why You Should Hold on to Roper (ROP) Stock for Now
Roper (ROP) stands to gain from acquired assets, healthy segmental business and operations in various markets. However, rising costs and buyout-related integration risks remain issues.
Mon, 17 Sep 2018
17:52:37 +0000
A Life Science Tools And Diagnostics Pair Trade: Goldman Recommends Buying Agilent, Moving to Sidelines On Thermo Fisher
Analyst Patrick Donnelly maintained a Buy rating on Agilent Technologies Inc (NYSE: A) and increased the price target from $77 to $82. The analyst added Agilent to Goldman's Americas Conviction List and also named it as a top pick. At the same time, Donnelly downgraded shares of Thermo Fisher Scientific Inc. (NYSE: TMO) from Buy to Neutral and maintained a $250 price target.
Mon, 17 Sep 2018
15:43:00 +0000
Thermo Fisher shares fall as Goldman downgrades to neutral; Agilent added to conviction list
Thermo Fisher Scientific Inc. shares slid 1.9% Monday, after Goldman Sachs downgraded the stock to neutral from buy on valuation grounds. Goldman removed Thermo Fisher from its Americas Conviction List and added Agilent Technologies Inc. , which it now deems its top pick in life science tools and diagnostics. Agilent shares rose 0.5%. "We see this as an opportunistic time to make the switch to A given the set-up and valuation, with Agilent providing a rare Tools opportunity to own an accelerating growth story at a reasonable valuation with untapped capital allocation upside that could potentially be unlocked by the new CFO in our view," analysts wrote in a note. On Thermo, "we believe our thesis for deal-driven accelerating growth and margin expansion has been more appropriately reflected in valuation while the company faces a difficult set of comps starting in 4Q18," they wrote. Goldman is still positive on the fundamentals of both companies, and expects beats and raises in the next few quarter. Analysts raised their stock price target for Agilent to $82 from $77, but kept its stock price target for Thermo at $250. Thermo shares have gained 29% since they were added to Goldman's Conviction List. Shares have gained 25% in 2018, while Agilent has gained 3.3%. The S&P 500 has gained 8%.
Mon, 17 Sep 2018
13:29:00 +0000
Altaba sells remaining stake in Yahoo Japan
The 'Squawk on the Street' team discusses the investment company selling the remaining shares.
Thu, 13 Sep 2018
13:02:21 +0000
What Analysts Project for Thermo Fisher
Wall Street analysts estimate Thermo Fisher Scientific (TMO) to report 14.1% growth in revenues to ~$23.9 billion in full-year 2018 as compared to $20.9 billion during 2017. EPS is estimated to be $10.99 during 2018 as compared to EPS of $9.49 during 2017. Analysts estimate the net adjusted income to increase to $4.5 billion during 2018 as compared to the net adjusted income of $3.8 billion during 2017.
Thu, 13 Sep 2018
11:32:45 +0000
Thermo Fisher to Acquire BDX’s Advanced Bioprocessing Business
Thermo Fisher Scientific (TMO) announced on September 7, 2018, that the company will acquire Becton Dickinson’s (BDX) advanced bioprocessing business.
Wed, 12 Sep 2018
21:00:02 +0000
Thermo Fisher to Offer Complete Cannabis Testing Solutions
Thermo Fisher Scientific (TMO) announced on September 7, 2018, that the company offers end-to-end analytical solutions that comply with cannabis testing standards as defined by Health Canada.
Wed, 12 Sep 2018
19:30:03 +0000
How Thermo Fisher Fared in the Second Quarter
Thermo Fisher Scientific (TMO) surpassed Wall Street analysts’ estimates for earnings per share (or EPS) and revenues during Q2 2018 and reported non-GAAP EPS of $2.75 on revenues of ~$6.1 billion during the quarter. The above chart compares the revenues since the first quarter of 2017.
Wed, 12 Sep 2018
17:55:03 +0000
How Thermo Fisher Scientific’s Valuation Looks in September
Thermo Fisher Scientific (TMO) provides equipment, software, analytical instruments, reagents, consumables, and services. Thermo Fisher reported non-GAAP EPS of $2.75 on revenues of ~$6.1 billion, a 21.8% increase as compared to ~$5.0 billion during the second quarter of 2017. The below chart compares revenues and EPS for Thermo Fisher Scientific since the first quarter of 2017.
Mon, 10 Sep 2018
13:30:01 +0000
Stock Market News For Sep 10, 2018
Markets ended sharply lower on Friday after President Donald Trump said that the United States was ready to move ahead with tariffs.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "This last year I have subscribed to two investment services, ValueForum and a well known income newsletter. ValueForum costs a little over 200 per year. The income newsletter costs about 400 per year. I am up 11% on investments made because I heard about them on ValueForum (of course, I do my own research on everything but the ideas came from ValueForum and there was always some discussion of the pros and cons of each investment on VF). I am down 8% on investments made because I heard about them from the income newsletter. I might also add that I often hear about breaking events immediately on ValueForum and a day or two later the same information is finally available from the newsletter. Hmmm...... which service is the better value?" more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards